Bristol Myers Squibb Announces Perioperative Nivolumab Plus Chemotherapy Significantly Improves Event-Free Survival in Resectable Non-Small Cell Lung Cancer

CheckMate -77T It is the second positive result achieved by Bristol-Myers Squibb in using immunotherapy combinations for non-metastatic non-small cell lung cancer.IIIPhase Research

This positive result further strengthens the evidence for Opdivo-based therapy in early-stage cancer. Opdivo has now been successful in six areas. ⅢIn the study period, it was confirmed to significantly improve the treatment outcomes of the corresponding tumor types, covering lung cancer, bladder cancer, and esophageal cancer./Cancer of the Gastroesophageal Junction and Melanoma

ShanghaiSeptember 25, 2023PR Newswire -- Bristol-Myers Squibb recently announced that the Phase III study CheckMate -77T met its primary endpoint assessed by Blinded Independent Central Review (BICR), demonstrating improved Event-Free Survival (EFS) in patients with resectable non-small cell lung cancer (NSCLC) at stages IIA to IIIB. In a pre-specified interim analysis, compared with neoadjuvant chemotherapy plus placebo, followed by surgery and adjuvant placebo treatment, the neoadjuvantOpdivo(Nivolumab) combined with chemotherapy, sequential surgery andOpdivoThe perioperative regimen for adjuvant treatment demonstrated a statistically significant and clinically meaningful improvement in EFS.OpdivoThe safety profile of the treatment regimen based on this is consistent with previously reported NSCLC studies.

"In recent years, we have made tremendous scientific progress in the treatment of non-metastatic NSCLC and remain committed to exploring new treatment options, with the hope of helping more patients achieve better long-term benefits."Vice President of Bristol-Myers Squibb Company, Global Head of Thoracic Oncology Program, M.D.Abderrahim OukessouRepresentation"Previously, the data we obtained in the CheckMate -816 study allowedOpdivo"Has become the only PD-1 inhibitor currently approved for neoadjuvant treatment of NSCLC. Today's results further solidify our leadership position in the field of resectable NSCLC and enrich our revolutionary scientific achievements in thoracic oncology. We sincerely thank the patients and researchers who participated in this trial: it is their efforts that have enabled us to further understand the significance of immunotherapy in the treatment of early-stage cancer patients."

Bristol-Myers Squibb will complete a comprehensive evaluation of the existing data from the CheckMate -77T study and looks forward to presenting the results at an upcoming medical conference. Meanwhile, the company will engage in discussions with health regulatory authorities regarding the relevant findings. The study is still ongoing to assess its secondary endpoint—overall survival (OS).

As of now,OpdivoCompared withOpdivoThe combination therapy based on has shown improved efficacy in the neoadjuvant, adjuvant, or perioperative treatment of four types of tumors, covering lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer, and melanoma.

The information contained in this material is for reference only. Please follow the advice or guidance of doctors or other healthcare professionals.

About CheckMate -77T

CheckMate -77T is a Phase III randomized, double-blind, placebo-controlled, multicenter study evaluating neoadjuvant therapy in 452 patients with resectable non-small cell lung cancer (NSCLC) staged IIA to IIIB.OpdivoCombined chemotherapy, sequential surgery andOpdivoAdjuvant Therapy: Comparing the Efficacy and Safety of Neoadjuvant Chemotherapy Combined with Placebo, Sequential Surgery, and Placebo Adjuvant Therapy. The primary endpoint of this study is Event-Free Survival (EFS). Secondary endpoints include Overall Survival (OS), Pathological Complete Response (pCR), and Major Pathological Response (MPR).

About the LungsCancer

Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer, accounting for 84% of all diagnosed cases. The majority of NSCLC diagnoses are non-metastatic patients (approximately 60%, of which up to half may be resectable), and this proportion is expected to increase over time with the growing adoption of screening. Although many non-metastatic NSCLC patients can be cured through surgery, 30% to 55% of patients experience recurrence and die from the disease after surgical removal, necessitating the use of treatments before surgery (neoadjuvant therapy) and/or after surgery (adjuvant therapy) to improve long-term outcomes.